X

Clinical Trials

Contact Us

Inoperable Stage I-III

A172401 (WF2304-A172401)

Complementary Options for Symptom Management In Cancer (COSMIC): Assessing Benefits and Harms of Cannabis and Cannabinoid Use Among a Cohort of Cancer Patients Treated in Community Oncology Clinics


EAY191-S3 (JIT – IF A POSSIBLE PATIENT IS IDENTIFIED, NOTIFY CRA ASAP AS IT WILL TAKE TIME TO OPEN TRIAL THROUGH NCORP)

Molecular Analysis for Combination Therapy Choice (ComboMATCH): Protocol EAY191-S3, Phase II Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants with AKT-Altered Advanced Non-Breast Solid Tumors


AFT-57

Randomized phase II trial of neoadjuvant and adjuvant atezolizumab with or without tiragolumab in conjunction with chemoimmunotherapy for unresectable stage III NSCLC


URCC 19185

Multicenter Randomized Controlled Trial comparing Brief Behavioral Therapy for Cancer Related Insomnia (BBT-CI) and Healthy Eating Education Learning (HEAL)


NRG-LU008

Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally-Advanced Non-Small Cell Lung Cancer


ALLIANCE A212102 **AT MBMC ONLY** **As of 8/1/23 the following Healthy Control Cohorts are Open (all others are Closed as of 2/22/23): Non-White Male Participants Age 60 or More Without Cancer Diagnosis and Non-White Male Participants Under Age 60 Without Cancer Diagnosis** **Effective with the release of Update #02, enrollment to the thyroid, melanoma, and sarcoma cancer cohorts has been closed.**

Blinded Reference Set For Multicancer Early Detection Blood Tests


URCC 19075 **MBMC ONLY**

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)


URCC-21038 ***Sites must enroll a Black patient and then be able to enroll a White patient within the following three months**

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting


S1933

A Pilot Study of Hypofractionated Radiotherapy Followed by Atezolizumab Consolidation in Stage II or III NSCLC Patients with Borderline Performance Status


URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue